The Longevity Fund

The Longevity Fund

A San Francisco-based venture capital firm that invests in companies that focus on extending the period of healthy human life and ameliorate age-related decline in physical function

The Longevity Fund is a venture capital firm in San Francisco that prefers to invest in companies that focus on extending the period of healthy human life and ameliorate age-related decline in physical function. Founded 2011 by Laura Deming in San Francisco, California, the firm invests in series A, series B, and series C rounds. The notable investment portfolio of The Longevity Fund includes Epirium Bio, eXo Imaging, Fauna Bio, Spring Discovery, System1 Biosciences, Decibel Therapeutics, Precision BioSciences, and UNITY Biotechnology. As of January 2020, The Longevity Fund has made 11 investments and two exits.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Precision BioSciences

Precision BioSciences is a biotechnology developing a gene editing platform for the creation of cell therapies, gene therapies, and agricultural products.

A biotechnology company developing drugs and treatments to diminish negative health effects associated with aging.

Spring Discovery is a computational drug discovery platform for age-related diseases founded by Ben Kamens.

ALX Oncology is a Burlingame, California-based biotechnology company working on pre-clinical stage immuno-oncology therapies.

5 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Laura Deming

Founder

Sten Tamkivi

Investor

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Alx Oncology

Decibel Therapeutics

Metacrine

Navitor Pharmaceuticals

Modulate mTOR activity

Precision Biosciences

Unity Biotechnology

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.